Oppenheimer Maintains Outperform on Lumos Pharma, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Lumos Pharma (NASDAQ:LUMO) but reduced the price target from $17 to $16.

December 11, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer has maintained an Outperform rating on Lumos Pharma but lowered the price target from $17 to $16.
While the reduction in price target could suggest a slightly less optimistic outlook on the stock's valuation, maintaining an Outperform rating indicates that Oppenheimer still sees positive potential in Lumos Pharma. The impact on the stock price is likely to be neutral in the short term as the positive rating balances the negative sentiment from the lowered target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100